Evaluation of Bone Cancer Treatment Techniques

Bone cancer is a serious morbidity and mortality factor that occurs in rare cases with less than ${1 \%}$ prevalence across all cancers. Despite being rare, bone cancer has a mortality rate, accounting for less than ${1 \%}$ of deaths worldwide and claiming about ${2, 1 0 0}$ people in the United States in 2022. This includes cancers in both adults and children. Most mortality cases are traced to the late detection of tumors and wrong systematic diagnostic and therapeutic decisional approaches deployed either by the concerned physicians, patients, or close associates. To circumvent the hurdles associated with poor therapeutic decision-making, relating to bone cancers and to eliminate scenarios associated with uncertainties in any decision-making platform, this study proposed the multicriteria decision-making (MCDM) method called fuzzy preference ranking organization method for enrichment evaluations (PROMETHEE) to compare, evaluate, and rank conventional and modern treatment approaches for bone cancer. Results from this study showed that, with a net flow of 0.1737, Radiofrequency was determined as the most preferred and most favorable treatment approach for bone cancer. Surgery, Cryotherapy, Immunotherapy, and Radiation therapy came second, third, fourth, and fifth with net flows of $0.1309,-0.0154,-0.0797$, and −0.0902 respectively. Chemotherapy with a net flow of $-{0 . 1 1 9 3}$ was the least preferred treatment alternative. However, the outranking results may differ if different weight preference functions are assigned to each selected criterion